Skip to main content
. 2014 Mar 25;111(14):5409–5414. doi: 10.1073/pnas.1316510111

Fig. 2.

Fig. 2.

The CX3CR1 inhibitor AZD8797 blocks MOG-EAE in DA rats. AZD8797 was administered through s.c. implanted osmotic minipumps to DA rats at day 8 after EAE induction. (A and B) Daily mean clinical score in groups of rats (n = 25–30) treated with either vehicle or AZD8797 in 39 µmol/kg per day (A) and 78 µmol/kg per day (B). (C) Mean score of EAE expressed as the percentage of vehicle treated rats during relapse phase versus plasma concentration of AZD8797. Data from 4 different EAE studies including 10 different treatment groups, with 25–30 rats per group. The in vivo IC50 was estimated at 2 µM (range, 1.5–4 µM).